Efficacy and Safety of Aceclofenac Controlled Release in Patients with Knee Osteoarthritis: A 4-week, Multicenter, Randomized, Comparative Clinical Study
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the analgesic effect, efficacy and safety of aceclofenac controlled release (CR) in patients with chronic knee osteoarthritis (OA).Materials and Methods: A total of 125 subjects with chronic knee OA were randomly divided into two groups: one group (n=62) was administered aceclofenac CR once daily and the other (n=63), aceclofenac immediate release (IR) twice a day for 4 weeks. A 100-mm visual analogue scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS) and range of motoin (ROM) were evaluated as the outcome measures. To evaluate the safety of the drug, adverse events, vital signs, physical examination findings, clinical laboratory values and electrocardiographic findings were evaluated.Results: The VAS, KOOS and ROM were improved after 4 weeks of administration in both groups, but the differences between the two groups were not statistically significant. Significant differences between the two groups were not shown in the evaluation of the adverse events, vital sign, physical examination results, clinical laboratory values, and electrocardiography.Conclusions: The aceclofenac CR and aceclofenac IR were equally effective in patients with chronic knee OA and the clinical trial results didn’t show any significant difference in safety. The new aceclofenac CR formulation was found to be effective and safe with the practical advantage of once daily administration.
Abstract
Purpose: To evaluate the analgesic effect, efficacy and safety of aceclofenac controlled release (CR) in patients with chronic knee osteoarthritis (OA).Materials and Methods: A total of 125 subjects with chronic knee OA were randomly divided into two groups: one group (n=62) was administered aceclofenac CR once daily and the other (n=63), aceclofenac immediate release (IR) twice a day for 4 weeks. A 100-mm visual analogue scale (VAS), Knee injury and Osteoarthritis Outcome Score (KOOS) and range of motoin (ROM) were evaluated as the outcome measures. To evaluate the safety of the drug, adverse events, vital signs, physical examination findings, clinical laboratory values and electrocardiographic findings were evaluated.Results: The VAS, KOOS and ROM were improved after 4 weeks of administration in both groups, but the differences between the two groups were not statistically significant. Significant differences between the two groups were not shown in the evaluation of the adverse events, vital sign, physical examination results, clinical laboratory values, and electrocardiography.Conclusions: The aceclofenac CR and aceclofenac IR were equally effective in patients with chronic knee OA and the clinical trial results didn’t show any significant difference in safety. The new aceclofenac CR formulation was found to be effective and safe with the practical advantage of once daily administration.
참고문헌 (29)
- Calis M, "Is intraarticular sodium hyaluronate injection an alternative treatment in patients with adhesive capsulitis?", Rheumatol Int, 26, pp.536~540 (2006)
- Rovetta G, "Intraarticular injection of sodium hyaluronate plus steroid versus steroid in adhesive capsulitis of the shoulder", Int J Tissue React, 20, pp.125~130 (1998)
- Lawrence RC, "Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States", Arthritis Rheum, 41, pp.778~799 (1998)
- Kelley WN, "Textbook of rheumatology" (1997), W.B. Saunders
- Vad VB, "Management of knee osteoarthritis : knee lavage combined with hylan versus hylan alone", Arch Phys Med Rehabil, 84, pp.634~637 (2003)
- Hochberg MC, "American College of Rheumatology", Arthritis Rheum, 38, pp.1541~1546 (1995)
- Tamai K, "Synovial response to intraarticular injections of hyaluronate in frozen shoulder : a quantitative assessment with dynamic magnetic resonance imaging", J Orthop Sci, 9, pp.230~234 (2004)
- Gowda KV, "Evaluation of bioequivalence of two formulations containing 100 milligrams of aceclofenac", Drug Dev Ind Pharm, 32, pp.1219~1225 (2006)
- Hinz B, "Simultaneous determination of aceclofenac and three of its metabolites in human plasma by high-performance liquid chromatography", Biomed Chromatogr, 17, pp.268~275 (2003)
- Dooley M, "Aceclofenac : a reappraisal of its use in the management of pain and rheumatic disease", Drugs, 61, pp.1351~1378 (2001)
- Cockburn J, "Effects of intervention on antibiotic compliance in patients in general practice", Med J Aust, 147, pp.324~328 (1987)
- Pareek A, "Efficacy and safety of aceclofenac in the treatment of osteoarthritis : a randomized double-blind comparative clinical trial versus diclofenac : an Indian experience", Curr Med Res Opin, 22, pp.977~988 (2006)
- Movilia PG, "Evaluation of the analgesic activity and tolerability of aceclofenac in the treatment of post-episiotomy pain", Drugs Exp Clin Res, 15, pp.47~51 (1989)
- Perez Busquier M, "Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis", Clin Rheumatol, 16, pp.154~159 (1997)
- Ward DE, "Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis", Clin Rheumatol, 14, pp.656~662 (1995)
- Kornasoff D, "Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis", Clin Rheumatol, 16, pp.32~38 (1997)
- Masso Gonzalez EL, "Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding", Arthritis Rheum, 62, pp.1592~1601 (2010)
- Bort R, "Metabolism of aceclofenac in humans", Drug Metab Dispos, 24, pp.834~841 (1996)
- Bort R, "Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human", Drug Metab Dispos, 24, pp.969~975 (1996)
- Henrotin Y, "In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators", Inflamm Res, 50, pp.391~399 (2001)
- Bae SK, "Pharmacokinetics of a new once-daily controlled-release formulation of aceclofenac in Korean healthy subjects compared with immediate-release aceclofenac and the effect of food : a randomized, open-label, three-period, crossover, single-centre study", Clin Drug Investig, 32, pp.111~119 (2012)
- Najib N, "Bioequivalence evaluation of two brands of aceclofenac 100 mg tablets(Aceclofar and Bristaflam)in healthy human volunteers", Biopharm Drug Dispos, 25, pp.103~108 (2004)
- Davies NM, "Clinical pharmacokinetics and pharmacodynamics of celecoxib : a selective cyclo-oxygenase-2 inhibitor", Clin Pharmacokinet, 38, pp.225~242 (2000)
- celecoxib in healthy male volunteers, "Drug Metab Dispos", 2000, 308~314
- Turck D, "A review of the clinical pharmacokinetics of meloxicam", Br J Rheumatol, 35(1), pp.13~16 (1996)
- Roos EM, "WOMAC Osteoarthritis Index : additional dimensions for use in subjects with post-traumatic osteoarthritis of the knee : Western Ontario and MacMaster Universities", Osteoarthritis Cartilage, 7, pp.216~221 (1999)
- Roos EM, "Knee injury and Osteoarthritis Outcome Score(KOOS) : validation of a Swedish version", Scand J Med Sci Sports, 8, pp.439~448 (1998)
- Roos EM, "Knee Injury and Osteoarthritis Outcome Score(KOOS) : development of a self-administered outcome measure", J Orthop Sports Phys Ther, 28, pp.88~96 (1998)
- Roos EM, "The Knee injury and Osteoarthritis Outcome Score(KOOS) : from joint injury to osteoarthritis", Health Qual Life Outcomes, 1, pp.64~ (2003)